American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 911-912 , May 2009

Plasma and Peritoneal Dialysate Levels During Daptomycin Therapy for Peritonitis

  • Dmytro Khadzhynov, MD

      Affiliations

    • Charité Universitätsmedizin Berlin, Charité Campus Mitte, Humboldt University, Berlin, Germany
  • ,
  • Christian Joukhadar, MD

      Affiliations

    • J&P Medical Research Ltd, Vienna, Austria
    • Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Harm Peters, MD

      Affiliations

    • Charité Universitätsmedizin Berlin, Charité Campus Mitte, Humboldt University, Berlin, Germany

  • Image Result

    (A) Peritoneal dialysis fluid and (B) blood trough concentrations of daptomycin in a patient with Gram-positive peritoneal dialysis–associated peritonitis. Daptomycin was given intravenously at a dose

    (A) Peritoneal dialysis fluid and (B) blood trough concentrations of daptomycin in a patient with Gram-positive peritoneal dialysis–associated peritonitis. Daptomycin was given intravenously at a dose of 5 mg/kg body weight every 48 hours (open arrows). Peritoneal dialysis fluid was collected at the end of 3 daytime 4-hour periods (2 L Physioneal® 2.27% each) and 1 overnight 12-hour dwell time (2 L Extraneal® 7.5% per day). Daptomycin concentrations were measured by using high-performance liquid chromatography.6 The patient's hospital discharge is indicated.

PII: S0272-6386(09)00517-4

doi: 10.1053/j.ajkd.2009.02.017

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 911-912 , May 2009